Reduction of proinflammatory cytokine expression in the synovium by targeting IKKβ in vivo in a rat model [1]

Arthritis and Rheumatism

Volumn 54, Issue 11, 2006, Pages 3716-3718

  Tas, Sander W ^a   Hajji, Najat ^a   Stenvers, Dirk J ^a   Firestein, Gary S ^b   Vervoordeldonk, Margriet J ^a   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GENE PRODUCT; GREEN FLUORESCENT PROTEIN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; PEROXIDASE; PREDNISOLONE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE TARGETING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO CULTURE; IN VIVO STUDY; INFLAMMATION; JOINT BIOPSY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; RAT; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; SYNOVIOCYTE; SYNOVITIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; GENE THERAPY; I-KAPPA B KINASE; INJECTIONS, INTRA-ARTICULAR; RATS; SYNOVITIS;

EID: 33750953841     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22188     Document Type: Article

References (21)

1. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κ B in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
2. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91.
3. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
4. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev 2004;18:2195-224.
5. Tak PP, Gerlag DM, Aupperle KR, van de Geest DA, Overbeek M, Bennett BL, et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum 2001;44:1897-907.
6. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003;62:635-8.
7. Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 2005;7:R862-7.
8. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
9. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.
10. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
11. Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, et al. Heterogeneous requirement of IκB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003;48:1901-12.
12. Wong PK, Campbell IK, Egan PJ, Ernst M, Wicks IP. The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover [review]. Arthritis Rheum 2003;48:1177-89.
13. Brightbill HD, Plevy SE, Modlin RL, Smale ST. A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 2000;164:1940-51.
14. Krane SM, Conca W, Stephenson ML, Amento EP, Goldring MB. Mechanisms of matrix degradation in rheumatoid arthritis. Ann N Y Acad Sci 1990;580:340-54.
15. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
16. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253:269-85.
17. McCachren SS. Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum 1991;34:1085-93.
18. Han R, Smith TJ. Induction by IL-1 β of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-γ. J Immunol 2005;174:3072-9.
19. Aicher WK, Alexander D, Haas C, Kuchen S, Pagenstecher A, Gay S, et al. Transcription factor early growth response 1 activity up-regulates expression of tissue inhibitor of metalloproteinases 1 in human synovial fibroblasts. Arthritis Rheum 2003;48:348-59.
20. Kadri Z, Maouche-Chretien L, Rooke HM, Orkin SH, Romeo PH, Mayeux P, et al. Phosphatidylinositol 3-kinase/Akt induced by erythropoietin renders the erythroid differentiation factor GATA-1 competent for TIMP-1 gene transactivation. Mol Cell Biol 2005;25:7412-22.
21. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sci U S A 1999;96:5668-73.